XBiotech Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

XBiotech hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.9%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$1.15
Prognose der Dividendenrendite	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

Nov 19

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von XBIT in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von XBIT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

XBiotech Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von XBIT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (XBIT)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Biotechs)	1.9%
Analystenprognose (XBIT) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von XBIT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von XBIT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von XBIT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da XBIT keine Ausschüttungen gemeldet hat.

XBiotech Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech: Several Shots On Goal In Big Target Market Indications

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Share price stability

XBiotech Inc. announced that it expects to receive $10 million in funding

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

Board Member exercised options to buy US$452k worth of stock.

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

Founder exercised options to buy US$9.8m worth of stock.

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

New 90-day high: US$19.83

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

New 90-day low: US$16.72

Independent Director notifies of intention to sell stock

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech's influenza-COVID-19 therapeutic cocktail shows effective anti-virus activity

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - US$19.95

New 90-day high - US$19.57

New 90-day high - US$16.08

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt

Gewinnausschüttung an die Aktionäre

Barausschüttung an die Aktionäre

Entdecken Sie dividendenstarke Unternehmen